Infrapopliteal Application of Paclitaxel-eluting Stents for Critical Limb Ischemia: Midterm Angiographic and Clinical Results

Siablis, Dimitris; Karnabatidis, Dimitris; Κατσάνος, Κωνσταντίνος; Diamantopoulos, Athanasios; Christeas, Nikolaos; Kagadis, George C.

doi:10.1016/j.jvir.2007.07.018

Cited by 61 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Siablis et al (22) evaluated the efficacy of paclitaxel DES in 32 limbs with CLI and observed that, at 9 Ϯ 4 months, the restenosis and occlusion rates were 77% and 24%, respectively. The reason for these less favorable outcomes is not clear, although these patients were treated with provisional stenting and dual platelet agents were discontinued after 6 months.…”

Section: Drug-eluting Stent Characteristicsmentioning

confidence: 99%

Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents

Feiring

Krahn

Nelson

et al. 2010

Journal of the American College of Cardiology

138

View full text Add to dashboard Cite

show abstract

Section: Drug-eluting Stent Characteristicsmentioning

confidence: 99%

Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents

Feiring

Krahn

Nelson

et al. 2010

Journal of the American College of Cardiology

138

View full text Add to dashboard Cite

show abstract

“…Renal disease and vessel occlusion were associated with worse outcomes. 36 Grant et al 37 reported 10 patients of whom 4 received PES to treat infrapopliteal arteries. At 1 year, the target revascularization rate was 10%.…”

Section: Infrapopliteal Diseasementioning

confidence: 99%

“…4,5,47 In contrast, sirolimuseluting-stents may be more efficacious than PES in the infrapopliteal distribution. 35,36,40 The utility of newer antiproliferatives, such as the sirolimus analogs, remains to be determined. 48 Patient and lesion characteristics are important considerations as well.…”

Section: Future Directionsmentioning

confidence: 99%

Local Paclitaxel Delivery for Treatment of Peripheral Arterial Disease

Hawkins

Hennebry

2011

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

“…From their first experience with infrapopliteal PES, they concluded to have reached acceptable clinical results, even though PES implantation failed to inhibit vascular restenosis and to decrease the need for repeat interventions. 18 Although evidence currently indicates that implantation of DES in the infrapopliteal vasculature leads to favorable outcomes with high mid-term primary patency and limb salvages rates, further support for the use of DES in patients with CLI and BK lesions will be gained from well-designed RCT. Such trials are about to start in conjunction with industry support.…”

Section: Drug Eluting Balloon-expandable Stentsmentioning

confidence: 99%

Current status of infrapopliteal artery stenting in patients with critical limb ischemia

et al. 2008

View full text Add to dashboard Cite

Due to the fear that early thrombosis and late luminal loss resulting from intimal hyperplasia might impede sustained patency of small-caliber arteries, such as those of the infrapopliteal bed, stent implantation in below-knee vessels remains controversial and is generally reserved for cases with a suboptimal outcome after percutaneous transluminal angioplasty (i.e. > 50% residual stenosis, flow-limiting dissection). Although evidence starts to build, favoring the use of stenting in the tibial area, results of well-conducted randomized controlled trials have to be awaited to change this strategy. Because of diameter similarities with coronary arteries, the first stents applied in the infrapopliteal vessels were all coronary devices. Once the feasibility of the stenting approach with these coronary products was shown, device manufacturers started to develop a dedicated infrapopliteal product range. To date, a broad spectrum of stent types has been used and investigated for the given indication. This article overviews the available literature and results of different balloon-expandable (bare metal, passive coated, drug eluting), self-expanding and absorbable stent types available for below-the-knee application and gives recommendations for future device technology advancements.Keywords: Stents, ischemia, arteriosclerosis. ResumoDevido ao receio de que a trombose precoce ou a estenose tardia por hiperplasia intimal possam impedir a manutenção da perviedade em vasos de pequeno calibre, o uso de stents pós-angioplastia no leito arterial infrapoplíteo permanece controverso e geralmente é reservado aos casos de resultado subótimo após angioplastia transluminal percutânea (isto é, estenose residual > 50% ou dissecção com limitação do fluxo). Apesar de evidências começarem a favorecer o uso de stents no segmento tibial, é necessário aguardar o resultado de ensaios controlados, randomizados e bem conduzidos para mudar esta estratégia. Sendo estes vasos infrapoplíteos de diâmetro similar às artérias coronárias, os primeiros stents usados neste segmento eram todos stents coronários. Uma vez que se mostrou exeqüível o uso destes stents, a indústria iniciou o desenvolvimento de uma linha de produtos específicos ao segmento infrapoplíteo. Atualmente uma gama de stents tem sido usada e investigada para este fim. Este artigo revê resultados disponíveis na literatura com diferentes stents expansíveis por balão (metal não-recoberto, revestimento passivo, eluição de fármacos), auto-expansíveis e absorvíveis disponíveis para o segmento infrapoplíteo e apresenta recomendações para os futuros avanços tecnológicos dos dispositivos.Palavras-chave: Stents, isquemia, arteriosclerose.

show abstract

Infrapopliteal Application of Paclitaxel-eluting Stents for Critical Limb Ischemia: Midterm Angiographic and Clinical Results

Cited by 61 publications

References 29 publications

Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents

Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents

Local Paclitaxel Delivery for Treatment of Peripheral Arterial Disease

Current status of infrapopliteal artery stenting in patients with critical limb ischemia

Contact Info

Product

Resources

About